Aktie A14398 IX BIOPHARMA LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen iX Biopharma Ltd.

Aktien

A14398

SG1BD9000009

42C

Markt geschlossen - Singapore S.E.
Andere Börsenplätze
 09:14:38 26.04.2024 		% 5 Tage % 1. Jan.
0.042 SGD +2.44% Intraday Chart für iX Biopharma Ltd. +5.00% -6.67%
12.03. Aktien in Singapur schließen marginal höher; Biopharma-Aktien steigen um 2% nach Einführung eines neuen sublingualen Wafers MT
12.03. IX Biopharma stellt neuen sublingualen Wafer vor MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer
IX Biopharma Introduces New Sublingual Wafer
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12%
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%
IX Biopharma Stays in Red in Fiscal H1
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10%
IX Biopharma Unit Launches Anti Ageing Products in US
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023
IX Biopharma Limited Unveils Development of Interferon Wafer to Complement Respiratory Viral Diseases
IX Biopharma Ltd. Announces Change of Registered Office Address
IX Biopharma Issues SG$2 Million Worth of Convertible Bonds to Private Investor
IX Biopharma Ltd. announced that it has received SGD 2 million in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14398 Aktie
  4. Nachrichten iX Biopharma Ltd.
  5. Andere Sprachen